GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TDS Pharm Co Ltd (XKRX:464280) » Definitions » Piotroski F-Score

TDS Pharm Co (XKRX:464280) Piotroski F-Score


View and export this data going back to 2024. Start your Free Trial

What is TDS Pharm Co Piotroski F-Score?

TDS Pharm Co does not have enough data to calculate Piotroski F-Score.


TDS Pharm Co Piotroski F-Score Historical Data

The historical data trend for TDS Pharm Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TDS Pharm Co Piotroski F-Score Chart

TDS Pharm Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A 6.00 8.00

TDS Pharm Co Quarterly Data
Dec20 Dec21 Dec22 Dec23
Piotroski F-Score N/A N/A 6.00 8.00

TDS Pharm Co  (XKRX:464280) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


TDS Pharm Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of TDS Pharm Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


TDS Pharm Co Business Description

Traded in Other Exchanges
N/A
Address
253 Pangyo-ro, Pangyo Inno Valley, Building C, Room 403, Bundang-gu, Gyeonggi-do, Seongnam-si, KOR, 13486
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.

TDS Pharm Co Headlines

No Headlines